Literature DB >> 8548414

Effects of simvastatin on plasma lipids and apolipoproteins in familial hypercholesterolemic swine.

J Hasler-Rapacz1, H J Kempen, H M Princen, B J Kudchodkar, A Lacko, J Rapacz.   

Abstract

Familial hypercholesterolemia (FHC) in swine, which resembles human familial combined hyperlipidemia, is a complex lipid and lipoprotein disorder associated with the development of severe coronary lesions similar to those occurring in advanced human coronary disease. The disorder is characterized by elevated plasma total cholesterol (TC), triglycerides (TG), LDL-cholesterol (LDL-C), apolipoproteins (apo) B, C-III, and E, and by decreased levels of HDL-cholesterol (HDL-C), apoA-I, and lecithin:cholesterol acyltransferase (LCAT) activity. A dose-response study with simvastatin, a specific inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, was conducted in four treatment groups of FHC animals, exhibiting TC > or = 250 mg/dL. The animals were fed 0, 80, 200, or 400 mg simvastatin daily for 3 weeks. The measured serum parameters included the levels of TC, VLDL-C, LDL-C, HDL-C, TG, lathosterol, apoA-I, B, C-III, and E, as well as LCAT activity. Simvastatin at 200 mg/d significantly decreased the levels of TC (-25%), LDL-C (-27%), lathosterol (-40%), apoB (-22%), apoC-III (-37%), and apoE (-24%) and modestly decreased the levels of HDL-C (-12%) and apoA-I (-11%) (percent relative to the average pretreatment and posttreatment baseline values) but did not affect the levels of TG, VLDL-C, the lathosterol/TC ratio, or LCAT activity. The levels of TC, LDL-C, apoB, and E were also lowered by simvastatin at 80 or 400 mg/d, but to a lesser extent than at 200 mg/d, while the other parameters were not influenced at these doses. The simvastatin-induced decreases of LDL-C, HDL-C, and apoA-I, B, C-III, and E were significantly correlated among each other. These results show that the trend of responses in TC, LDL-C, apoB, apoC-III, and apoE to simvastatin in the FHC swine is similar to that observed in humans, although the drugs is less potent and efficacious in swine, while the results are different from those in humans with regard to the remaining parameters.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8548414     DOI: 10.1161/01.atv.16.1.137

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  6 in total

1.  Simvastatin preserves diastolic function in experimental hypercholesterolemia independently of its lipid lowering effect.

Authors:  Dallit Mannheim; Joerg Herrmann; Piero O Bonetti; Ronit Lavi; Lilach O Lerman; Amir Lerman
Journal:  Atherosclerosis       Date:  2011-02-24       Impact factor: 5.162

2.  Epicardial fat gene expression after aerobic exercise training in pigs with coronary atherosclerosis: relationship to visceral and subcutaneous fat.

Authors:  Joseph M Company; Frank W Booth; M Harold Laughlin; Arturo A Arce-Esquivel; Harold S Sacks; Suleiman W Bahouth; John N Fain
Journal:  J Appl Physiol (1985)       Date:  2010-10-14

3.  Displacement and strain estimation for evaluation of arterial wall stiffness using a familial hypercholesterolemia swine model of atherosclerosis.

Authors:  Wenqi Ge; Christian G Krueger; Ashley Weichmann; Dhanansayan Shanmuganayagam; Tomy Varghese
Journal:  Med Phys       Date:  2012-07       Impact factor: 4.071

Review 4.  Investigating the Metabolic Syndrome: Contributions of Swine Models.

Authors:  Xin Zhang; Lilach O Lerman
Journal:  Toxicol Pathol       Date:  2016-03-01       Impact factor: 1.902

5.  Animal models of calcific aortic valve disease.

Authors:  Krista L Sider; Mark C Blaser; Craig A Simmons
Journal:  Int J Inflam       Date:  2011-08-02

6.  The effects of simvastatin or interferon-α on infectivity of human norovirus using a gnotobiotic pig model for the study of antivirals.

Authors:  Kwonil Jung; Qiuhong Wang; Yunjeong Kim; Kelly Scheuer; Zhenwen Zhang; Quan Shen; Kyeong-Ok Chang; Linda J Saif
Journal:  PLoS One       Date:  2012-07-23       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.